Endometriosis drug effective in trials.
Endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. drug effective in trials
An experimental drug is showing promise against endometriosis, a common and painful disease of the female reproductive system reproductive system, in animals, the anatomical organs concerned with production of offspring. In humans and other mammals the female reproductive system produces the female reproductive cells (the eggs, or ova) and contains an organ in which development of the fetus that is frequently associated with infertility. In what is reported to be the largest, most carefully controlled study of its kind, the drug -- a synthetic molecule taken as a nasal spray -- proved as effective as the only currently approved treatment and was reported to cause significantly fewer side effects Side effects
Effects of a proposed project on other parts of the firm. .
Affecting as many as 1 in 15 women of reproductive age, endometriosis occurs when tissue from the uterine lining migrates to other parts of the body, usually in the vicinity of the reproductive tract, and begins to grow. These islands of tissue remain responsive to monthly releases of reproductive hormones, which can cause a painful inflammatory response. Treatment has revolved around suppressing secretion of the female hormone estrogen.
Only one drug, danazol, made by New York City-based Sterling Drug Co., is approved for treatment of endometriosis in the United States. But danazol is a derivative of the male hormone testosterone and has a number of undesirable side effects, including voice lowering, increased growth of body hair, liver damage and a shift in blood lipid levels similar to those associated with cardiovascular disease. For women who cannot tolerate danazol, the only effective intervention is surgical removal of the ovaries Ovaries
The female sex organs that make eggs and female hormones.
Mentioned in: Choriocarcinoma
ovaries (ō´v .
The new drug, nafarelin, made by Syntex Research in Palo Alto, Calif., belongs to a class of synthetic compounds called gonadotropin-releasing hormone (GnRH) agonists. These chemicals resemble naturally occurring GnRH, which normally stimulates pituitary pituitary /pi·tu·i·tary/ (pi-too´i-tar?e)
2. pituitary gland; see under gland.
anterior pituitary adenohypophysis. secretion of reproductive hormones. They differ from natural GnRH, however, in that they bind more readily to pituitary receptors and are less easily broken down by regulatory enzymes. Scientists have found that these tenacious analogues confuse hormonal regulatory controls so that estrogen production is suppressed.
The latest research was led by Milan R. Henzl, head of Reproductive Medicine at Syntex and an assistant clinical professor at the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). at San Francisco, and was performed at 20 research centers in the United States and abroad. It involved double-blind comparisons of nafarelin and danazol in 213 women over a six-month span, using a standardized measure of endometriosis severity that included periodic examination of endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium.
n relating to the end-ometrium or cavity of the uterus. masses by laparoscopy laparoscopy
Procedure for inspecting the abdominal cavity using a laparoscope; also surgery requiring use of a laparoscope. Laparoscopes use fibre-optic lights and small video cameras to show tissues and organs on a monitor. . The study, which appears in the Feb. 25 NEW ENGLAND JOURNAL OF MEDICINE The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. , shows that more than 80 percent of the patients in both groups had significant reduction of endometriosis, with nafarelin causing far fewer side effects.
"Nafarelin has a very straightforward action," says Henzl, "but it's a new class of compounds and we still must be quite cautious about it." Previous studies have shown that GnRH agonists cause some loss of bone mass, although the loss appears to be reversible. Other side effects include hot flashes and decreased libido.